Cover Image
Market Research Report

Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 909648
Published Content info 157 Pages
Delivery time: 1-2 business days
Price
Back to Top
Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
Published: August 28, 2019 Content info: 157 Pages
Description

About this market

Technavio's chronic myelogenous leukemia (CML) therapeutics market analysis considers sales from targeted therapy, chemotherapy, and immunotherapy. Our analysis also considers the sales of chronic myelogenous leukemia (CML) therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing number of approvals for orphan drug destinations will play a significant role in the targeted therapy segment to maintain its market position. Also, our global chronic myelogenous leukemia (CML) therapeutics market report looks at factors such as advent of novel therapies, patient assistance programs for TKIs, and strategic alliance. However, patent expiration of TKIs, availability of substitutes, and late diagnosis of CML may hamper the growth of the chronic myelogenous leukemia (CML) therapeutics industry over the forecast period.

Overview

Strategic alliances

The global CML therapeutics market has witnessed multiple strategic alliances in recent years. Vendors in the global CML therapeutics market are also collaborating to expand their distribution networks and overcome challenges associated with the high cost of R&D of CML therapeutics. These alliances include license agreement among educational institutions, support groups, pharma, and diagnostic companies. Furthermore, the collaborations with foundations and support groups also contribute to market growth by increasing patient adherence by reducing the cost burden. In March 2019, BMS in collaboration with The Max Foundation to assist cancer patients who are unable to access the treatment. This will lead to the expansion of the global chronic myelogenous leukemia (CML) therapeutics market at a CAGR of almost 6% during the forecast period.

Development of diagnostic tests and predictive markers

The companies that develop diagnostic methods are conducting research on developing new diagnostic testing methods that could help in an early detection of CML for treating diseases effectively using therapeutics. These developments include diagnostic kit in oncology which can effectively monitor the molecular response of the indication at an early stage. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global chronic myelogenous leukemia (CML) therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global chronic myelogenous leukemia (CML) therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic myelogenous leukemia (CML) therapeutics manufacturers, that include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.

Also, the chronic myelogenous leukemia (CML) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR31940

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Immunotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

  • Emergence of pipeline molecules
  • Development of diagnostic tests and predictive markers
  • Increasing research in regenerative medicines

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Immunotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Immunotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Boehringer Ingelheim International GmbH - Vendor overview
  • Exhibit 51: Boehringer Ingelheim International GmbH - Product segments
  • Exhibit 52: Boehringer Ingelheim International GmbH - Organizational developments
  • Exhibit 53: Boehringer Ingelheim International GmbH - Geographic focus
  • Exhibit 54: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibit 55: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 56: Boehringer Ingelheim International GmbH - Key customers
  • Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 58: Bristol-Myers Squibb Co. - Product segments
  • Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 61: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 62: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Product segments
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 70: Merck & Co. Inc. - Vendor overview
  • Exhibit 71: Merck & Co. Inc. - Product segments
  • Exhibit 72: Merck & Co. Inc. - Organizational developments
  • Exhibit 73: Merck & Co. Inc. - Geographic focus
  • Exhibit 74: Merck & Co. Inc. - Segment focus
  • Exhibit 75: Merck & Co. Inc. - Key offerings
  • Exhibit 76: Merck & Co. Inc. - Key customers
  • Exhibit 77: Mylan NV - Vendor overview
  • Exhibit 78: Mylan NV - Product segments
  • Exhibit 79: Mylan NV - Organizational developments
  • Exhibit 80: Mylan NV - Geographic focus
  • Exhibit 81: Mylan NV - Segment focus
  • Exhibit 82: Mylan NV - Key offerings
  • Exhibit 83: Mylan NV - Key customers
  • Exhibit 84: Novartis AG - Vendor overview
  • Exhibit 85: Novartis AG - Product segments
  • Exhibit 86: Novartis AG - Organizational developments
  • Exhibit 87: Novartis AG - Geographic focus
  • Exhibit 88: Novartis AG - Segment focus
  • Exhibit 89: Novartis AG - Key offerings
  • Exhibit 90: Novartis AG - Key customers
  • Exhibit 91: Otsuka Holdings Co. Ltd. - Vendor overview
  • Exhibit 92: Otsuka Holdings Co. Ltd. - Product segments
  • Exhibit 93: Otsuka Holdings Co. Ltd. - Organizational developments
  • Exhibit 94: Otsuka Holdings Co. Ltd. - Geographic focus
  • Exhibit 95: Otsuka Holdings Co. Ltd. - Segment focus
  • Exhibit 96: Otsuka Holdings Co. Ltd. - Key offerings
  • Exhibit 97: Otsuka Holdings Co. Ltd. - Key customers
  • Exhibit 98: Pfizer Inc. - Vendor overview
  • Exhibit 99: Pfizer Inc. - Product segments
  • Exhibit 100: Pfizer Inc. - Organizational developments
  • Exhibit 101: Pfizer Inc. - Geographic focus
  • Exhibit 102: Pfizer Inc. - Segment focus
  • Exhibit 103: Pfizer Inc. - Key offerings
  • Exhibit 104: Pfizer Inc. - Key customers
  • Exhibit 105: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 106: Takeda Pharmaceutical Co. Ltd. - Product segments
  • Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 111: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 112: Teva Pharmaceutical Industries Ltd. - Product segments
  • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 114: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 115 Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 116: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 117: Validation techniques employed for market sizing
  • Exhibit 118: Definition of market positioning of vendors
Back to Top